今日の臨床サポート 今日の臨床サポート
関連論文:
img  1:  Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes.
 
著者: Takahiro Suzuki, Masao Tomonaga, Yasushi Miyazaki, Shinji Nakao, Kazuma Ohyashiki, Itaru Matsumura, Yutaka Kohgo, Yoshiro Niitsu, Seiji Kojima, Keiya Ozawa
雑誌名: Int J Hematol. 2008 Jul;88(1):30-5. doi: 10.1007/s12185-008-0119-y. Epub 2008 Jun 27.
Abstract/Text Many patients with bone marrow failure syndromes need frequent transfusions of red blood cells, and most of them eventually suffer from organ dysfunction induced by excessively accumulated iron. The only way to treat transfusion-induced iron overload is iron chelating therapy. However, most patients have not been treated effectively because daily/continuous administration of deferoxamine is difficult for outpatients. Recently, a novel oral iron chelator, deferasirox, has been developed, and introduction of the drug may help many patients benefit from iron chelation therapy. In this review, we will discuss the current status of iron overload in transfusion-dependent patients, and the development of Japanese guidelines for the treatment of iron overload in Japan, which were established by the National Research Group on Idiopathic Bone Marrow Failure Syndromes in Japan.

PMID 18581199  Int J Hematol. 2008 Jul;88(1):30-5. doi: 10.1007/s12185-008-0119-y. Epub 2008 Jun 27.
戻る

さらなるご利用にはご登録が必要です。

こちらよりご契約または優待日間無料トライアルお申込みをお願いします。

(※トライアルご登録は1名様につき、一度となります)


ご契約の場合はご招待された方だけのご優待特典があります。

以下の優待コードを入力いただくと、

契約期間が通常12ヵ月のところ、14ヵ月ご利用いただけます。

優待コード: (利用期限:まで)

ご契約はこちらから